In the spotlight

Approval of Donanemab

Donanemab is part of a newer class of therapies designed to slow the progression of Alzheimer’s disease.

3 minutes

Why are women more likely to develop Alzheimer’s disease?

Nearly two-thirds of the 6.2 million people with Alzheimer’s disease aged 65 or older in the U.S. are women.

4 minutes

The differences between normal aging and dementia

It is important to distinguish between memory loss related to normal aging and signs of serious neurocognitive disorders such as Alzheimer’s disease.

10 minutes

Cognitive vitality: Practical Strategies to Promote Brain Health

Presented by Laura Middleton

Accompagner sans s’oublier : les clés pour les proches aidants

Présenté par Virginie Kieffer et Jessika Cecchini

Articles
Events
Catch up – The Thursday Chats